Health AI Central
Share:
Peer-Reviewed Publication
Eur Heart J Cardiovasc Imaging2026;27(5):1012-1021.April 30, 2026Journal Article

Lipoprotein(a) selectively associates with vulnerable coronary plaque phenotypes in comparison with other established risk markers.

Rebecca Fisher1, Chen Gurevitz2,3, Edward A Fisher1, Jisuk Park4, Melissa Aquino4, Sascha N Goonewardena5, Robert S Rosenson2
1Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
2Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, 1428 Madison Avenue, Atran | 8th Floor, New York, NY 10029, USA.
3Cardiology Division, Rabin Medical Center, Petah-Tikva, Israel.
4Cleerly Inc., Denver, CO, USA.
5Department of Cardiology, University of Michigan, Ann Arbor, MI, USA.
PubMed DOI

Abstract

AIMS: Lipoprotein(a) [Lp(a)] is an inherited cardiovascular risk factor. However, its association with coronary plaque characteristics beyond traditional risk enhancers remains unclear. We aimed to evaluate the association between Lp(a) levels and coronary plaque characteristics in asymptomatic primary prevention patients, and to compare its predictive value against other risk enhancers, including…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.